title: [Hypersensitivity to 5-aminosalicylic acid. Value of desensitization by oral route].
abstract: BACKGROUND
  Treatment with sulphasalazine of patients with mild and moderate forms of Crohn's disease may result in side effects in some of them.
  
  
  METHODS
  An 11-year-old girl with Crohn's disease was given 40 mg/kd/day of sulphasalazine after achieving remission with prednisone. She developed urticaria and eosionophilia 8 days later, then extended skin edema during a second course of sulphasalazine requiring methyl prednisolone therapy. Mesalazine administration (25 mg/kg/day), one month later, resulted to watery stools, vomiting, and fever, a side effect observed again after two further mesalazine challenges of one-month interval. Eosionophilia was present and the lymphocyte stimulation test with mesalazine was positive. Successful desensitization to sulphasalazine could be obtained 9 months later permitting further safe administration of this drug up to 18 months.
  
  
  CONCLUSIONS
  Hypersensitivity to sulphasalazine may be successfully overcame by oral desensitization, especially in those patients with low-grade activity of Crohn's disease.
authors.affiliation: Unité d'hépatogastroentérologie et nutrition pédiatriques, hôpital Edouard-Herriot, Lyon, France.
authors.forename: A
authors.initials: A
authors.lastname: Lachaux
authors.forename: C
authors.initials: C
authors.lastname: Le Gall
authors.forename: I
authors.initials: I
authors.lastname: Loras-Duclaux
authors.forename: A
authors.initials: A
authors.lastname: Aboufadel
authors.forename: M
authors.initials: M
authors.lastname: Hermier
mesh_terms: D000284:Administration, Oral; D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D019804:Mesalamine; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D012460:Sulfasalazine; D019804:Mesalamine
vernacular_title: Hypersensibilité à l'acide 5-aminosalicylique. Intérêt de la désensibilisation par voie orale.